Spine Biologics Market

Spine Biologics Market Size (2024 to 2029)

As per our report, the global market size for spine biologics was worth USD 1.88 Billion in 2024 and is estimated to grow at a CAGR of 4.4%, reaching USD 2.33 billion by 2029. Spine biologics plays a vital role in spine injuries. For example, these are used in disc diseases, spinal cord injuries, and spinal fusion surgeries.

Current Scenario of the Spine Biologics Market

The materials that alter the surrounding environment by using active cellular processes for growth promotion and differentiation as an alternative to traditional treatments, aiding in the repair and healing of injury called spinal biologics; can actively increase bone formation by attracting more cells to the fusion site and stimulating spinal fusion. In addition, they decrease the frequency of additional surgeries by decreasing soft tissue disruption; therefore, they successfully achieve arthrodesis in treating symptomatic deformities. When one or more discs deteriorate in the spine due to age, degenerative disc diseases occur with back or neck pain, which cell therapies can treat (e.g., stem cells and chondrocytes), Biomolecular therapies (e.g., genes and proteins). And total disc replacement (allogeneic or tissue-engineered).

MARKET DRIVERS

YOY growth in the incidence of spine-related health issues is primarily accelerating the global spine biologics market growth.

People affected by spinal disorders are significantly growing around the world. Population over 60 years are more likely to be prone to spine problems and undergo fusion surgeries as treatment, which significantly boosts the global spine biologics market growth. Being a subject of controversies in studies, evidence, and possible complications, It has become an important part of spine surgeries. Using bone grafts is an essential advantage for surgeons to consider biological healing of the actual fusion, without which the fusion cannot be performed. According to a study conducted by the Annals of Rheumatic Diseases, one person in every ten suffers from Lower Back Pain (LBP). According to a report published in 2013 by the World Health Organization (WHO), a range of 250,000 to 300,000 are suffering from spinal cord injuries. Most of the injuries are causing due to road accidents, violence, and various falls. As per the National Spinal Cord Injury Statistical Centre (NSCISC), in 2017, around 285,000 people in the U.S. were reported to have been diagnosed with different spinal cord injuries.

YOY growth in the prevalence of overweight is another major factor driving the spine biologics market growth.

As a critical element in the fusion healing process, autografts require a separate surgical incision to remove bone from an area outside the spine, with a new incision and significant morbidity potential. Furthermore, due to the limited availability of autografts, Bone can usually only be removed from an area once, posing a problem for patients requiring additional surgery; as per the estimates, adults of 1.9 billion were overweight in 2019, of which 650 million were obese. Furthermore, growing healthcare expenditure and technological developments are further fuelling market growth. Furthermore, the increasing number of minimally invasive spine surgeries is expected to lavish the growth rate of the global spine biologics market.

MARKET RESTRAINTS

High costs associated with surgeries for spinal disorders; unfavorable reimbursement policies of various governments are majorly limiting the global spine biologics market growth.

Strict rules and regulations by the government in approving new products and their launch regarding people's safety is a challenging factors for the key players. In addition, allografts, being of human origin, are osteoconductive and osteoinductive, deficient in viable cells due to the sterilization procedure, and lack osteogenic characteristics. Additional limitations involve undesirable alterations in bone matrix composition and the restricted risk of infection with HBV or HCV during the radiation sterilization procedure. Further, the lack of complete knowledge of spine biologics and treatment procedures hinders market growth to a small extent.

Impact of COVID-19 On The Global Spine Biologics Market

A new coronavirus, currently known as severe acute respiratory syndrome coronavirus 2, is responsible for the COVID-19 disease outbreaks (SARS-CoV-2). In the current pandemic caused by the highly contagious SARS-COV-2 virus, spine surgeons play an important role in treating acute and emergent spinal diseases while improving patient and provider protections and reducing healthcare resource utilization. Biomaterials for treating degenerative disc disease, spinal cord injuries, and bone replacement surgery make up the field of spine biologics. In spine surgery, the use of these products has always been important.

Spinal fusion is a surgery that corrects the spine's small bones (vertebrae). Spine Biologics Market has had moderate growth during this pandemic. Spine injuries are more common in people over 50 and are more prone to structural changes in the spine or spinal impairments. As the world's senior population grows, so will the need for care and diagnosis of these conditions. This is especially important since many spine patients could be at a higher risk of advancing to a severe stage of COVID-19.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Spine Biologics Market Analysis By Surgery type

Based on surgery type, the anterior cervical discectomy and fusion segment contributed the majority of the share to the market in 2022. It is a surgical and safe procedure with relatively rare and manageable complications, treating nerve root or spinal cord compression. It is a type of neck surgery involving removing a damaged disc by decompressing the spinal cord and nerve roots in the cervical spine to relieve pressure on the spinal cord and relieve pain, followed by intervertebral fusion to stabilize the corresponding vertebrae. The growth is due to the increase in cervical cancer patients driving the market growth.

On the other hand, during the forecast period, the transforaminal lumbar inter-body fusion segment is witnessed to have fast growth following anterior cervical discectomy and fusion. TLIF surgery is a spinal fusion surgery where the neurosurgeon accesses the lower spine through the intervertebral foramen performed to join two or more spinal vertebrae, eliminating any movement between them by replacing the intervertebral disc with a bone graft.

Global Spine Biologics Market Analysis  By Product type

The bone grafts substitute segment accounted for a significant market share based on product type in 2022. This segment is likely to produce more profits across the spine biologics market. It is due to the high requirement by surgeons with a growing number of spine procedures. Bone graft substitutes are biomaterials, natural or synthetic, used to stabilize the implant by providing a scaffold for new bone growth, potentially improving fracture healing by augmenting altered cellular and molecular mechanisms. These generally contain dicalcium phosphate, hydroxyapatite, tricalcium phosphate, calcium phosphate cement, and calcium sulfate, also used for osteoporotic fracture treatment. Moreover, according to the patient medical history, the accessibility of advanced products in various shapes and sizes makes this segment grow high.

Under the bone graft sector, allografts, bones were taken from a tissue bank for use in medical procedures, are foreseen to dominate the market owing to its numerous benefits of preparation in several different forms (such as chips) for use in spinal fusion, immediate structural support, absence of the need for additional surgery to remove bone, and osteoconductivity by reducing surgery time and wound healing.

REGIONAL ANALYSIS

Regionally, the global market was dominated by the North American spine biologics market in 2021 and is predicted to showcase its dominating trend throughout the forecast period over the other regions. The North American market is estimated to grow at a CAGR value of 4.2% from 2021 to 2026. The market in North America is increasing due to the factors like raising funds from the government, a moderate increase in diseases in the older population, and the growing income of hospitals and people.

The European spine biologics market is projected to showcase promising growth during the forecast period. Advancements in technologies, a growing number of hospitals, and an increasing patient pool in spine biologics are majorly soaring the market growth in this region.

The spine biologics market in Asia Pacific is expected to grow at a CAGR of 4.9% from 2021 to 2026. The region is expected to have strong growth. It is likely to enlarge at a higher rate due to the increasing population, rising medical quality, and increasing awareness in countries like India and China.

The Latin American spine biologics market is estimated to be worth USD 301 million by 2026. The factor that boosts the market is lifestyle changes which increase obesity-related problems in people.

The spine biologics market in Middle East & Africa is anticipated to have steady growth in the forthcoming years and throughout the period. In addition, the launch of reimbursement policies from the government favoring ordinary people and raising awareness among the population is fueling the market growth.

KEY PLAYERS IN THE SPINE BIOLOGICS MARKET

Some of the notable companies operating in the global spine biologics market profiled in the report are Alphatec Holdings, Inc., Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., RTI Surgical, Inc., SeaSpine and Zimmer Biomet Holdings, Inc.

RECENT MARKET DEVELOPMENTS

• In October 2022, Orthofix, a global medical device company specializing in spine and orthopedics, entered into a definitive merger agreement with a global medical technology company for surgical spine treatment solutions, SeaSpine, which would become, with highly complementary biologics, a world-leading spine and orthopedic company, leading surgical navigation system.

• In October 2022, the International University of Health and Wellness at Mita Hospital in Tokyo used Royal Philips Augmented Reality (A.R.) surgical navigation solution, ClarifEye, for the first patient's treatment in Japan to bring surgery invasive spinal colon, highlighting the positive results post-surgery.

• In February 2020, SeaSpine holding company made a strategic association with 7DSurgical Inc. to focus on the surgical solution to treat spinal disorders.
• In May 2020, NuVasive, a leader in spine technologies, announced its expansion of advanced materials science by introducing a Modulus XLIF Dual-sided plate and received 510 (k) clearance U.S FDA for the same.
• In August 2018, RTI Surgical Holding Inc. agreed with Aziyo Biologics. As per the agreement, Aziyo Company offers its ViBone device support to RTI Surgical, which is used to repair bone to perform auto-grafts for various orthopedic surgeries.

DETAILED SEGMENTATION OF THE GLOBAL SPINE BIOLOGICS MARKET INCLUDED IN THIS REPORT
 

This research report on the global spine biologics market has been segmented and sub-segmented based on the product, surgery, and region.

By Surgery type

• Anterior Cervical Discectomy and Fusion  
• Posterior Lumbar Interbody Fusion             
• Transforaminal Lumbar Interbody Fusion 
• Anterior Lumbar Interbody Fusion              
• Lateral Lumbar Interbody Fusion  

By Product type

• Bone Graft              
• Autograft
• Allograft
• Bone Graft Substitutes      
• Synthetic Bone Grafts
• Demineralized Bone Matrix
• Bone Morphogenetic Proteins
• Platelet-Rich Plasma            
• Bone Marrow Aspirate Therapy     

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa